Boston Scientific says unlikely to meet sales, forecast after cyberattack
Boston Scientific (BSX) announced it will not meet its 2026 sales and profit forecasts due to a cyberattack disrupting operations. The incident, first identified on August 25, caused network outages affecting manufacturing and order processing. The company expects partial revenue recovery but remains uncertain about the full financial impact. Shares fell 2.3% in morning trading. BSX had previously forecast 2026 adjusted earnings of $3.28-$3.32 per share and 5.5%-6.5% sales growth. It plans to up
How this was made
The 30-second read
Why it matters
The guidance downgrade may trigger sell pressure, but recovery of operations could limit downside.
Market read
Guidance miss due to cyber risk is material for investors and may influence sector sentiment.
What to watch
Potential insurance recoveries and backlog clearing could mitigate long‑term impact.
Background
Boston Scientific disclosed a cyberattack that halted manufacturing and order shipments, prompting a revision of its 2026 guidance.
Ticker impact
Boston Scientific announced it will not meet its 2026 sales and earnings forecasts after a cyberattack disrupted operations.
Potential short-term decline as investors reassess 2026 outlook.
The company explicitly revised its guidance due to a material operational disruption, a clear catalyst for price movement.
Market effects
Highlights cyber risk exposure for medical device sector, may affect peers like Abbott, Stryker, Medtronic.
U.S. healthcare stocks could see heightened volatility.
Raises concerns for global med‑tech supply chains.
Counterpoint
If the disruption is short‑lived, the market may overreact; a rebound could present a buying opportunity.
Key entities
- CompanyBoston Scientific
Medical device maker issuing the guidance revision.
